title: Asenapine sensitization from adolescence to adulthood and its potential molecular basis.
abstract: Asenapine is a new antipsychotic drug that induces a long-lasting behavioral sensitization in adult rats. The present study investigated the developmental impacts of adolescent asenapine treatment on drug sensitivity and on 3 proteins implicated in the action of antipsychotic drugs (i.e. brain-derived neurotrophic factor (BDNF), dopamine D2 receptor, and ΔFosB) in adulthood. Male adolescent Sprague-Dawley rats (postnatal days, P 43-48) were first treated with asenapine (0.05, 0.10 or 0.20mg/kg, sc) and tested in the conditioned avoidance or PCP (2.0mg/kg, sc)-induced hyperlocomotion tasks for 5 days. After they became adults (∼P 76), asenapine sensitization was assessed in a single avoidance or PCP-induced hyperlocomotion challenge test with all rats being injected with asenapine (0.10mg/kg, sc). Rats were then sacrificed 1 day later and BDNF, D2 and ΔFosB in the prefrontal cortex, striatum and hippocampus were examined using Western blotting. In adolescence, repeated asenapine treatment produced a persistent and dose-dependent inhibition of avoidance response, spontaneous motor activity and PCP-induced hyperlocomotion. In the asenapine challenge test, adult rats treated with asenapine (0.10 and 0.20mg/kg) in adolescence made significantly fewer avoidance responses and showed a stronger inhibition of spontaneous motor activity than those previously treated with saline. However, no group difference in the levels of BDNF, D2 and ΔFosB expression was found. These findings suggest that although adolescent asenapine treatment for a short period of time induces a robust behavioral sensitization that persists into adulthood, such a long-term effect is not likely to be mediated by BDNF, D2 and ΔFosB.
authors.affiliation: Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, PR China; Department of Psychology, University of Nebraska-Lincoln, USA.
authors.forename: Qing
authors.initials: Q
authors.lastname: Shu
authors.affiliation: Department of Neurology, The Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, PR China; Department of Psychology, University of Nebraska-Lincoln, USA; Department of Neurology, Changzhou No. 2 People's Hospital, Nanjing Medical University, Changzhou, Jiangsu, PR China.
authors.forename: Rongyin
authors.initials: R
authors.lastname: Qin
authors.affiliation: Department of Neurology, The Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, PR China.
authors.forename: Yingzhu
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu, PR China. Electronic address: ghu@njmu.edu.cn.
authors.forename: Gang
authors.initials: G
authors.lastname: Hu
authors.affiliation: Department of Psychology, University of Nebraska-Lincoln, USA. Electronic address: mli@unl.edu.
authors.forename: Ming
authors.initials: M
authors.lastname: Li
mesh_terms: D000367:Age Factors; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D003986:Dibenzocycloheptenes; D006576:Heterocyclic Compounds, 4 or More Rings / Q000008:administration & dosage / Q000494:pharmacology*; D006948:Hyperkinesis / Q000139:chemically induced; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D010622:Phencyclidine / Q000633:toxicity; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D014828:Vocalization, Animal / Q000187:drug effects
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D003986:Dibenzocycloheptenes; C483820:Fosb protein, rat; D006576:Heterocyclic Compounds, 4 or More Rings; D016760:Proto-Oncogene Proteins c-fos; D017448:Receptors, Dopamine D2; D010622:Phencyclidine; C522667:asenapine
keywords: Asenapine; BDNF; Conditioned avoidance response; Dopamine D(2) receptor; Phencyclidine; ΔFosB
references.citation: Hum Psychopharmacol. 2006 Oct;21(7):433-8
references.pmid: 17029305
references.citation: Behav Brain Res. 2013 Feb 1;238:178-87
references.pmid: 23092709
references.citation: J Neurosci. 2007 Mar 14;27(11):2979-86
references.pmid: 17360921
references.citation: Expert Opin Ther Targets. 2006 Aug;10(4):515-31
references.pmid: 16848689
references.citation: Synapse. 2006 Feb;59(2):92-100
references.pmid: 16270300
references.citation: Psychiatr Serv. 2008 May;59(5):554-60
references.pmid: 18451016
references.citation: Eur Neuropsychopharmacol. 2005 May;15(3):311-7
references.pmid: 15820421
references.citation: Science. 1995 Oct 27;270(5236):593-8
references.pmid: 7570017
references.citation: Psychopharmacology (Berl). 2014 Apr;231(8):1649-1659
references.pmid: 24363078
references.citation: Int J Neuropsychopharmacol. 2013 Aug;16(7):1599-609
references.pmid: 23351612
references.citation: Eur Neuropsychopharmacol. 2010 Mar;20(3):187-94
references.pmid: 19875272
references.citation: Schizophr Bull. 2011 Nov;37(6):1257-69
references.pmid: 20439320
references.citation: Synapse. 2012 Jul;66(7):650-60
references.pmid: 22362425
references.citation: Eur J Neurosci. 1994 Apr 1;6(4):668-71
references.pmid: 8025717
references.citation: Eur Neuropsychopharmacol. 1999 Jan;9(1-2):165-70
references.pmid: 10082243
references.citation: J Neurosci Res. 2003 Jan 1;71(1):127-31
references.pmid: 12478621
references.citation: Psychopharmacologia. 1975;41(2):97-104
references.pmid: 1171492
references.citation: Expert Opin Drug Discov. 2013 Jan;8(1):93-103
references.pmid: 23121334
references.citation: J Psychopharmacol. 2009 Jan;23(1):65-73
references.pmid: 18308814
references.citation: Biol Psychiatry. 2009 Dec 1;66(11):1038-46
references.pmid: 19726031
references.citation: Behav Brain Res. 2010 Dec 25;214(2):240-7
references.pmid: 20561963
references.citation: Psychopharmacology (Berl). 2008 Feb;196(3):417-29
references.pmid: 17940749
references.citation: Psychopharmacology (Berl). 1984;84(3):347-51
references.pmid: 6440181
references.citation: Neuropharmacology. 2013 Dec;75:356-64
references.pmid: 23954676
references.citation: Psychopharmacology (Berl). 2008 May;198(1):103-11
references.pmid: 18297468
references.citation: PLoS One. 2013;8(2):e57308
references.pmid: 23437365
references.citation: Pediatrics. 2008 May;121(5):1002-9
references.pmid: 18450906
references.citation: Psychopharmacology (Berl). 2010 Sep;212(1):45-57
references.pmid: 20623111
references.citation: Biol Psychiatry. 2004 Mar 1;55(5):457-63
references.pmid: 15023572
references.citation: J Psychopharmacol. 2014 Apr;28(4):363-75
references.pmid: 24257809
references.citation: Arch Gen Psychiatry. 2006 Jun;63(6):679-85
references.pmid: 16754841
references.citation: Behav Brain Res. 2013 Nov 15;257:286-94
references.pmid: 24103641
references.citation: Drugs Today (Barc). 2009 Dec;45(12):865-76
references.pmid: 20135021
references.citation: J Neurosci. 2008 Sep 24;28(39):9797-805
references.pmid: 18815264
references.citation: Psychopharmacology (Berl). 2009 Jan;202(1-3):295-306
references.pmid: 18925388
references.citation: Behav Pharmacol. 2012 Aug;23(4):380-91
references.pmid: 22732209
references.citation: Eur Neuropsychopharmacol. 2014 Jun;24(6):986-95
references.pmid: 24440552
references.citation: Brain Res. 2002 Nov 1;954(1):11-20
references.pmid: 12393228
references.citation: NeuroRx. 2006 Jan;3(1):10-21
references.pmid: 16490410
references.citation: Neurosci Res. 2011 Dec;71(4):335-40
references.pmid: 21893111
references.citation: Behav Pharmacol. 1993;4(4):289-312
references.pmid: 11224198
references.citation: Pharmacol Biochem Behav. 2010 May;95(3):298-307
references.pmid: 20167232
references.citation: Neuropsychopharmacology. 2013 Feb;38(3):513-24
references.pmid: 23132270
references.citation: Psychopharmacology (Berl). 2011 Apr;214(4):843-53
references.pmid: 21088957
references.citation: Neuron. 2002 Nov 14;36(4):675-88
references.pmid: 12441056
references.citation: Schizophr Bull. 2010 May;36(3):607-23
references.pmid: 18845557
references.citation: Synapse. 2000 Aug;37(2):167-9
references.pmid: 10881038
references.citation: Psychopharmacology (Berl). 2009 Nov;206(4):699-714
references.pmid: 19462162
references.citation: Eur Neuropsychopharmacol. 2009 Feb;19(2):77-84
references.pmid: 18845422
references.citation: J Neurosci Res. 2000 Jun 15;60(6):783-94
references.pmid: 10861791
references.citation: J Comp Neurol. 1996 Oct 07;374(1):70-83
references.pmid: 8891947
references.citation: Eur J Neurosci. 2001 Jul;14(1):135-44
references.pmid: 11488957
references.citation: Brain Res Mol Brain Res. 2004 Dec 20;132(2):146-54
references.pmid: 15582154
references.citation: Psychopharmacology (Berl). 1997 Jan;129(1):79-84
references.pmid: 9122367
references.citation: Brain Behav Immun. 2012 Feb;26(2):353-63
references.pmid: 22154704
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:177-85
references.pmid: 24140929
references.citation: J Psychopharmacol. 2010 Mar;24(3):341-8
references.pmid: 18719049
references.citation: Schizophr Res. 2006 Feb 15;82(1):95-106
references.pmid: 16442781
references.citation: Pharmacol Biochem Behav. 1990 Feb;35(2):291-300
references.pmid: 2320636
references.citation: Synapse. 1999 Aug;33(2):118-28
references.pmid: 10400890
references.citation: Neuropsychopharmacology. 2007 Mar;32(3):607-15
references.pmid: 16823391
references.citation: Behav Pharmacol. 2012 Feb;23(1):66-79
references.pmid: 22157143